Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42October 22, 2025 10:04 AM EDT | Source: Hemostemix Inc.Calgary, Alberta--(Newsfile Corp. - October 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, peripheral arterial disease, chr ...

Accessibility StatementSkip Navigation TORONTO, Oct. 22, 2025 /PRNewswire/ -- Visionary Holdings Inc. ("GV" or the "Company"), a technology- driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced the signing of a strategic cooperation agreement with Jiangsu Yike Regenerative Medical Technology Co., Ltd. ("Yike") to jointly establish Visionary Yike Stemcell Technologies Inc., a Canada-based joint venture dedicated to advancing stem cell research, clinical application, and commercializ ...

Adia Nutrition Inc. Appoints Dr. Evan Thomas, MD, PhD, to Drive Adia Med's Specialized Treatment RevolutionOctober 21, 2025 9:00 AM EDT | Source: Adia Nutrition Inc.Winter Park, Florida--(Newsfile Corp. - October 21, 2025) -  Adia Nutrition Inc. (OTCQB: ADIA) is excited to announce the appointment of Evan Thomas, MD, PhD, as an Independent Medical Director for its medical division, Adia Med. A renowned radiation oncologist and visionary, Dr. Thomas will oversee clinic practices, including the ...

公司近期活动 - 公司首席财务官Richard Kincaid将于2025年10月21日下午2点（美国东部时间）在纽约举行的Chardan第9届年度遗传医学会议上发表演讲[1] - 活动提供网络直播，直播录像将在Chardan网站上保留60天[1] 公司业务概览 - 公司是日本领先的临床阶段生物技术公司，专注于利用干细胞开发再生医学疗法[2] - 公司成立于2011年，自2015年起在东京证券交易所成长市场上市（代码：4593）[2] 核心技术平台与产品管线 - 公司在体干细胞领域开发MultiStem®（HLCM051），这是一种源自健康成人捐赠者骨髓的多能成体祖细胞（MAPCs）专有细胞产品[2] - MultiStem®已显示出强大的抗炎和免疫调节特性，在数百名患者的后期临床试验中证明了安全性并提示了疗效，并可在3D生物反应器中大规模稳定生产[2] - 公司计划在全球范围内推进MultiStem®用于治疗ARDS、创伤和缺血性中风[2] - 在iPSC再生医学领域，公司开发了HLCN061，这是一种通过基因编辑功能增强的用于实体瘤的下一代NK细胞疗法，在动物模型中显示出强大的抗肿瘤功效，并正在与Akatsuki Therapeutics合作准备进行首次人体试验[2] - 公司已建立一个专有的、经过基因编辑的“通用供体”诱导多能干细胞系，用于开发针对免疫肿瘤学、眼科、肝脏疾病及其他医疗需求严重未满足领域的下一代再生疗法[2]

核心观点 - 公司宣布其用于治疗角膜内皮功能障碍继发角膜水肿的候选产品AURN001在1/2期CLARA试验中获得积极的12个月结果 [1] 临床试验结果 - 试验评估了AURN001（neltependocel联合Y-27632 rho激酶抑制剂）的安全性、有效性和耐受性 [1] - 试验结果涵盖12个月的数据 [1] 公司及产品定位 - 公司为临床阶段再生医学公司 [1] - 公司使命为数百万患者恢复视力 [1] - 候选产品AURN001由人类角膜内皮细胞组成 [1]

Mesoblast Limited (NASDAQ:MESO) is one of the best hot stocks to invest in. On October 3, Mesoblast Limited announced that its product Ryoncil (remestemcel-L-rknd) was assigned a specific Healthcare Common Procedure Coding System/HCPCS J-Code by the US Medicare & Medicaid Services/CMS. The new permanent J-Code, J3402, became active for billing and reimbursement on October 1. The formal recognition by CMS is a commercial milestone as it provides a standardized, clear, and permanent billing pathway for Ryon ...

Adia Nutrition Paves Way for Nasdaq and New Investors Through SEC Form 10 SubmissionOctober 14, 2025 9:00 AM EDT | Source: Adia Nutrition Inc.Winter Park, Florida--(Newsfile Corp. - October 14, 2025) - Adia Nutrition Inc. (OTCQB: ADIA) is thrilled to announce a major milestone in its growth journey. The Company has engaged an independent public accounting firm and securities counsel to prepare and file its Form 10 registration statement with the U.S. Securities and Exchange Commission (SEC). T ...

First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery diseaseCelularity PDA-002 achieved durable wound healing with just two intramuscular dosesAs a qualified stem cell therapy under Florida statute (§ 458.3245), effective July 1, 2025 authorizing use in wound care, orthopedics, and pain management, PDA-002 may offer licensed Florida physicians an important new tool in treating DFU patients. FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq ...

North Bergen, New Jersey--(Newsfile Corp. - October 9, 2025) -  Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company"), is pleased to announce that it has completed the first step in the closing process with Revive Regenerative, Inc. The Company has secured the initial tranche of capital required in the amount of $500,000 as set forth in the merger agreement. In addition, the Company has finalized with GSS Capital to raise the additional $3,000,000 needed, with the terms agreed to by both sides. The partie ...

盘后整体表现 - 美股盘后生物技术和医疗保健板块出现大量看涨活动，多只股票上涨并创下52周新高 [1][6] Turn Therapeutics Inc (TTRX) - 公司股价在纳斯达克首个交易日盘后飙升134.29%至16.40美元，较常规交易时段收盘价上涨9.40美元 [1] Talphera Inc (TLPH) - 公司股价在常规交易时段创下52周新高后，盘后再涨4.55%至1.38美元，此轮上涨由市场动能驱动 [2] Personalis Inc (PSNL) - 公司股价延续上涨趋势，盘后上涨1.50%至8.81美元，日内曾触及52周新高，投资者对精准肿瘤学的兴趣是潜在推动力 [2] Ionis Pharmaceuticals Inc (IONS) - 公司股价盘后上涨3.64%至72.51美元，此前在公司创新日活动中重申其研发管线战略并预计到2026年将有多个独立产品上市，推动股价在常规交易时段创下52周新高 [3] Sensei Biotherapeutics Inc (SNSE) - 公司股价盘后上涨5.23%至12.08美元，公司计划于10月20日公布研发管线更新，事件前的提前布局可能推动股价上涨 [3] Corbus Pharmaceuticals Holdings Inc (CRBP) - 公司股价盘后上涨4.77%至14.06美元，公司计划参加10月9日Piper Sandler虚拟肿瘤学研讨会，预计将公布其肿瘤学项目更新 [4] Longeveron Inc (LGVN) - 公司股价盘后上涨5.71%至0.9801美元，公司计划在ROTH医疗保健机会会议上进行展示，可能提供其再生医学管线的见解 [4] Palisade Bio Inc (PALI) - 公司股价盘后上涨5.00%至2.10美元，股价在几天前完成1.38亿美元公开募股后维持高位，该募股为其主要胃肠道候选药物进入二期试验前增强了资产负债表 [5] 行业驱动因素 - 盘后交易活动反映了技术性突破、事件驱动预期和动量交易的结合，多只股票创下新高或在关键会议前上涨，生物技术板块继续为盘后波动和机会提供沃土 [6]